Early Ebola vaccine shows promise in first-stage testing

The first experimental Ebola vaccine has shown promise in early clinical study by the National Institutes of Health, said. The researchers now plan to take the vaccine in a larger study in West Africa in the coming months.
The researchers found that the vaccine produces an immune response in 20 adults who participated in the study in man, a good sign that the drug might protect against the virus. Drugs, collaboration, dangerous by the National Institutes of Health and GlaxoSmithKline, which developed any party side effects. The only side effect was fever all day in some volunteers who received higher doses.

"Based on the positive results of the first study in humans this vaccine candidate, we continue our accelerated plan larger studies to determine if the vaccine is effective in the prevention of Ebola virus infection," Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at NIH, said.

The vaccine was prepared from segments of genetic material from two samples Ebola virus. The vaccine can not cause Ebola. The process uses 20 volunteers aged 18 to 50 the number of persons aged 10 received vaccine injections with a lower dose and 10 at a higher dose. After the tests, the researchers found that the volunteers developed anti-Ebola antibodies. The largest studies in West Africa are expected to begin later this year or early 2015.